{"id":9791,"date":"2024-06-06T07:31:00","date_gmt":"2024-06-06T12:31:00","guid":{"rendered":"https:\/\/ibio.org\/?p=9791"},"modified":"2024-06-06T07:31:00","modified_gmt":"2024-06-06T12:31:00","slug":"biopharma-sector-experiences-shift-in-venture-funding-and-investment-trends-in-q1-2024","status":"publish","type":"post","link":"https:\/\/ibio.org\/biopharma-sector-experiences-shift-in-venture-funding-and-investment-trends-in-q1-2024\/","title":{"rendered":"Biopharma Sector Experiences Shift in Venture Funding and Investment Trends in Q1 2024"},"content":{"rendered":"

The biopharma sector has undergone significant changes in venture funding and investment trends during the first quarter of 2024, according to a recent PitchBook report<\/a>. Despite a decrease in deal count, the sector saw an increase in venture funding, with $7.4 billion raised across 188 deals compared to $6.3 billion across 248 deals in Q4 2023. This shift indicates a stabilization in the market, defining a new normal until federal interest rates change.<\/p>\n

Investor sentiment remained optimistic, particularly following the J.P. Morgan Healthcare Conference, which led to a brief surge in IPO momentum. Exits, including IPOs and M&A, totaled $6.9 billion across 23 deals in Q1 2024, up from $5.4 billion across 26 deals in Q4 2023. This increase in exit value, despite a slight decrease in the number of deals, suggests a continued focus on quality investments and a preference for mature clinical data.<\/p>\n

Emerging technologies and therapeutics, such as cancer vaccines led by mRNA leaders Moderna, BioNTech, and CureVac, continued to progress, potentially renewing interest in mRNA technology. Engineered B-cell therapeutics startups, including Immusoft and Be Biopharma, also showed potential despite setbacks related to high costs and scientific risks.<\/p>\n

Companies continued to work in the new-normal funding environment, focusing on asset-centric investments. The biopharma sector witnessed a shift toward quality investments, with investors concentrating on fewer, more promising bets. The market favored clinical validation and asset-centric investments, with a growing preference for mature clinical data before proceeding with IPOs.<\/p>\n

Early-stage outliers in AI and obesity treatments continued to attract significant investment. The impact of GenAI remains more evident on the funding side, highlighting investor hopes for long-term impact on drug development, while short-term productivity gains are apparent across industries.<\/p>\n

This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe<\/a> to receive top industry headlines delivered straight to your inbox.<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

The biopharma sector has undergone significant changes in venture funding and investment trends during the first quarter of 2024, according to a recent PitchBook report. Despite a decrease in deal count, the sector saw an increase in venture funding, with $7.4 billion raised across 188 deals compared to $6.3 billion across 248 deals in Q4 […]<\/p>\n","protected":false},"author":12,"featured_media":9723,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[526],"tags":[489,553,89,557,503,556,124,285,485],"class_list":["post-9791","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-newsbrief","tag-ai","tag-funding","tag-ibio","tag-mrna","tag-newsbrief","tag-obesity","tag-pharmaceutical","tag-startup","tag-venture-capital"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/9791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=9791"}],"version-history":[{"count":2,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/9791\/revisions"}],"predecessor-version":[{"id":9793,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/9791\/revisions\/9793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/9723"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=9791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=9791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=9791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}